Hefei Chuangxin Pharmaceutical Technology

Hefei Chuangxin Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Hefei, China, specializing in the development of targeted small molecule therapies. The company utilizes a proprietary kinase-focused drug discovery platform, which integrates high-throughput screening and structural biology to identify novel inhibitors for oncology and inflammatory indications. Its lead clinical program, CX-1002, is a dual FLT3 and AXL inhibitor designed to overcome resistance in patients with acute myeloid leukemia. Beyond its internal pipeline, the company offers contract research and development services, leveraging its expertise in medicinal chemistry and pharmacology. Hefei Chuangxin was founded by scientists from the Chinese Academy of Sciences and maintains a strong focus on translational medicine.